The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist
In December 2022, GSK entered into an exclusive license agreement with biopharma company Zhimeng for CB06-036, a TLR8 agonist. Subject to...
top of page
Sage Group News
AeroNeph Therapeutics Announces Search for Strategic Partners for Novel Drugs for Renal Disease
Birmingham, Alabama, and London, England, 1 September 2022 – AeroNeph Therapeutics (“AeroNeph”; www.aeroneph.com), a pioneer in discovery...
Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed
See full Press Release by clicking the link below!
Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder
Sage’s new client, Kinnov Therapeutics, is a French-based company focused on one of the major unmet global healthcare challenges,...
Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment
Hatchtech has engaged the Sage Group to manage the sale process for its lead asset Xeglyze®. Xeglyze is a patent protected, single...
Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol
Our new client DisperSol Technologies, Inc. (https://www.dispersoltech.com/) is a private, Austin, Texas-based drug development company...
Opportunity in Cellular Immunotherapy with oNKord Unmodified Natural Killer Cells from Glycostem
Glycostem Therapeutics B.V. (“Glycostem” or the “Company”). Glycostem is a cell therapy company focused on developing stem cell-derived...
bottom of page